Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
2.100
+0.320 (17.98%)
Apr 9, 2026, 1:08 PM EDT - Market open
Milestone Pharmaceuticals Employees
Milestone Pharmaceuticals had 38 employees as of December 31, 2025. The number of employees increased by 5 or 15.15% compared to the previous year.
Employees
38
Change (1Y)
5
Growth (1Y)
15.15%
Revenue / Employee
$40,684
Profits / Employee
-$1,659,421
Market Cap
257.56M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 38 | 5 | 15.15% |
| Dec 31, 2024 | 33 | -14 | -29.79% |
| Dec 31, 2023 | 47 | 8 | 20.51% |
| Dec 31, 2022 | 39 | 10 | 34.48% |
| Dec 31, 2021 | 29 | 1 | 3.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Codexis | 146 |
| Voyager Therapeutics | 141 |
| MediWound | 121 |
| OmniAb | 89 |
| Compugen | 75 |
| Fennec Pharmaceuticals | 35 |
| Enlivex | 34 |
MIST News
- 2 days ago - Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 7 days ago - Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 days ago - Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies - GlobeNewsWire
- 20 days ago - Why Milestone Pharma Stock Is Taking A Dive Today - Benzinga
- 20 days ago - Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT - GlobeNewsWire
- 20 days ago - Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Benzinga
- 24 days ago - Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session - GlobeNewsWire
- 4 weeks ago - Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026 - GlobeNewsWire